Improving immune therapy for liver cancer by targeting specific immune cells
Official title: Targeting KLF2 in macrophages to improve immune checkpoint therapy for hepatocellular cancer
Funded at University of Connecticut Sch of Med/dnt · NIH-11172570 · Data updated 2026-11-12
This study is looking at a new way to improve treatment for liver cancer by using a special protein in immune cells and a type of bacteria, hoping to help patients get better results from their therapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Connecticut Sch of Med/dnt NIH-funded |
| Lab location | 1 site (Farmington, United States) |
| Project start | May 1, 2023 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $627,562 |
| NIH project number | 5R01CA274959-03 |
| Project ID | NIH-11172570 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with hepatocellular cancer who are seeking new treatment options.
✕Less likely to help
Patients with liver cancer who are not eligible for immune checkpoint therapies or those with other types of cancer may not benefit from this research.
What this research studies
This research focuses on enhancing immune checkpoint therapy for hepatocellular cancer (HCC) by targeting a specific protein called KLF2 in macrophages. The researchers have developed a unique mouse model that closely mimics human liver cancer, allowing them to study how the immune system interacts with tumors. They are investigating a novel approach that combines immune therapy with a specific type of bacteria to improve treatment outcomes. By understanding the cellular and molecular mechanisms involved, the goal is to create more effective therapies for patients with HCC.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for liver cancer, potentially improving survival rates for patients.
How similar studies have gone: Other research has shown promise in enhancing immune therapies through innovative approaches, suggesting potential for success in this area.
Where this research is happening
-
University of Connecticut Sch of Med/dnt
Farmington, United States Active
Researchers
- Principal investigator: Li, Guangfu — University of Connecticut Sch of Med/dnt
- Study coordinator: Li, Guangfu
Related research
Other NIH-funded projects on the same topics.
-
Lowering KLF2 in immune cells to boost immunotherapy for liver cancer
Researchers are trying to see if reducing a gene called KLF2 in certain immune cells can help immunotherapy work better for people with liver cancer.
-
Investigating how gut bacteria can enhance immune response against liver cancer
This study is looking at how the bacteria in our gut can help treat liver cancer by using a special mouse model, and it hopes to find ways to boost the immune system and improve treatment results for people with this condition.
-
Using gut bacteria to help the immune system fight liver cancer
Researchers are seeing if changing gut bacteria can help the immune system respond better to liver cancer treatments like anti-PD-1 therapy.
-
Investigating how cholecystokinin receptors affect liver cancer
This study is looking at how certain receptors in the body can affect liver cancer growth and spread, and it aims to find new ways to treat this type of cancer that could help patients in the future.
-
PF-08634404 alone or with ipilimumab for adults with advanced hepatocellular carcinoma not removable by surgery
This tests PF-08634404 by itself and together with ipilimumab in adults whose hepatocellular carcinoma is advanced and cannot be removed surgically.
-
Assessing blood biomarkers and MRI for liver cancer patients undergoing radiation therapy
This study is testing if using special MRI scans and blood tests can help doctors keep track of liver health in patients with liver cancer who are getting radiation therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.